CMLYM23020 // S2114 // Reagan
Basic Study Information
Purpose:Location: University of Rochester
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit
patients who have received chemotherapy (fludarabine and cyclophosphamide) followed
by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene
ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has
come back (recurrent) or that does not respond to treatment (refractory) or grade
IIIb follicular lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere
with the ability of cancer cells to grow and spread. Polatuzumab vedotin is a monoclonal
antibody, called polatuzumab, linked to a drug called vedotin. Polatuzumab is a form
of targeted therapy because it attaches to specific molecules (receptors) on the surface
of cancer cells, and delivers vedotin to kill them. Chemotherapy drugs, such as fludarabine
and cyclophosphamide, work in different ways to stop the growth of cancer cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of
immune system cell) are changed in the laboratory so they will attack cancer cells.
T cells are taken from a patient's blood. Then the gene for a special receptor that
binds to a certain protein on the patient's cancer cells is added to the T cells in
the laboratory. The special receptor is called a chimeric antigen receptor. Large
numbers of the CAR T cells are grown in the laboratory and given to the patient by
infusion for treatment of certain cancers. Giving mosunetuzumab and/or polatuzumab
vedotin after chemotherapy and CAR T-cell therapy may be more effective at controlling
or shrinking the cancer than not giving them.
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search